Wells Fargo Initiates Coverage On ITeos Therapeutics with Overweight Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on ITeos Therapeutics with an Overweight rating and a price target of $31.
August 13, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on ITeos Therapeutics with an Overweight rating and a price target of $31.
The initiation of coverage with an Overweight rating and a specific price target by a major financial institution like Wells Fargo is likely to positively impact the stock price of ITeos Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100